CD86 and neoplasm: FeAMV treatment elicited superior DC maturation (CD11c+CD86+ cells) versus monotherapies (Fig. 18j, k), achieving maximal tumor growth inhibition and M1/M2 polarization (Fig. 18l), confirming combinatorial ferroptosis–bacterial immunotherapy efficacy.